Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Unity Biotechnology, Inc. (NASDAQ: UBX).

Full DD Report for UBX

You must become a subscriber to view this report.


Recent News from (NASDAQ: UBX)

Unity Biotechnology reports Q3 results
Unity Biotechnology (NASDAQ: UBX ): Q3 GAAP EPS of -$0.45. More news on: Unity Biotechnology, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 16:49
UNITY Biotechnology, Inc. Reports Third Quarter 2018 Financial Results
SAN FRANCISCO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported third quarter 2018 financial results. "...
Source: GlobeNewswire
Date: November, 07 2018 16:05
UNITY Biotechnology, Inc. to Announce Third Quarter 2018 Financial Results
SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the third quarter ended Septe...
Source: GlobeNewswire
Date: October, 31 2018 16:05
Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for...
Source: SeekingAlpha
Date: October, 28 2018 09:11
Unity Biotech shares halted on volatility, up 18%
Thinly traded Unity Biotechnology ( UBX +17.8% ) is up on more than double normal volume before Nasdaq suspended trading due to volatility. More news on: Unity Biotechnology, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: September, 13 2018 14:07
UNITY Biotechnology, Inc. to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
SAN FRANCISCO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard, chairman and chief e...
Source: GlobeNewswire
Date: September, 05 2018 16:05
Unity Biotechnology reports Q2 results
Unity Biotechnology (NASDAQ: UBX ): Q2 EPS of -$0.76 More news on: Unity Biotechnology, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 09 2018 16:39
UNITY Biotechnology, Inc. Reports Second Quarter 2018 Financial Results
SAN FRANCISCO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported second quarter 2018 financial results. ...
Source: GlobeNewswire
Date: August, 09 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1325,921104,20524.8750Cover
2018-12-1222,392108,08820.7165Cover
2018-12-1148,904113,32743.1530Short
2018-12-1059,084145,25540.6761Short
2018-12-0727,37779,26434.5390Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on UBX.


About Unity Biotechnology, Inc. (NASDAQ: UBX)

Logo for Unity Biotechnology, Inc. (NASDAQ: UBX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: UBX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 07 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: June, 07 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: May, 04 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 03 2018
      Filing Type: CERTFiling Source: edgar
      Filing Date: May, 02 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: May, 02 2018

       

       


      Daily Technical Chart for (NASDAQ: UBX)

      Daily Technical Chart for (NASDAQ: UBX)


      Stay tuned for daily updates and more on (NASDAQ: UBX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: UBX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in UBX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of UBX and does not buy, sell, or trade any shares of UBX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/